Table. Characteristics of Case Patients With COVID-19 by Vaccination Status and Control Patients Without COVID-19.
| Characteristic | No. (%) | ||
|---|---|---|---|
| Vaccinated cases (n = 314) | Unvaccinated cases (n = 1669) | Controls (n = 2530) | |
| Age, median (IQR), y | 67 (55-74) | 53 (40-63) | 62 (48-71) |
| Age, y | |||
| 18-49 | 54 (17.2) | 704 (42.2) | 690 (27.3) |
| 50-64 | 82 (26.1) | 574 (34.4) | 756 (29.9) |
| ≥65 | 178 (56.7) | 391 (23.4) | 1084 (42.8) |
| Sex | |||
| Women | 138 (43.9) | 831 (49.8) | 1233/2530 (48.7) |
| Men | 176 (56.1) | 838 (50.2) | 1297/2528 (51.3) |
| Race and ethnicity | |||
| Black, non-Hispanic | 55 (17.5) | 453 (27.1) | 529 (20.9) |
| Hispanic, any race | 44 (14.0) | 381 (22.8) | 294 (11.6) |
| White, non-Hispanic | 201 (64.0) | 717 (43.0) | 1587 (62.7) |
| Othera | 14 (4.5) | 118 (7.1) | 120 (4.7) |
| US census region | |||
| South | 143 (45.5) | 741 (44.4) | 959 (37.9) |
| Midwest | 76 (24.2) | 323 (19.4) | 709 (28.0) |
| West | 61 (19.4) | 381 (22.8) | 519 (20.5) |
| Northeast | 34 (10.8) | 224 (13.4) | 343 (13.6) |
| Resident of long-term care facility | 15/307 (4.9) | 25/1602 (1.6) | 140/2436 (5.7) |
| Previous hospitalization in last year | 131/302 (43.4) | 381/1496 (25.5) | 1299/2390 (54.4) |
| Current tobacco use | 21/290 (7.2) | 154/1392 (11.1) | 466/2282 (20.4) |
| No. of chronic medical conditions, median (IQR)b | 3 (2-4) | 1 (0-2) | 2 (1-3) |
| Cardiovascular disease | 236 (75.2) | 814/1667 (48.8) | 1675/2527 (66.3) |
| Pulmonary disease | 100 (31.8) | 327/1667 (19.6) | 732/2527 (29.0) |
| Diabetes | 112 (35.7) | 425/1667 (25.5) | 809/2527 (32.0) |
| Immunocompromising conditionc | 128 (40.8) | 191/1667 (11.5) | 585/2527 (23.1) |
| Obesity (body mass index ≥30) | 142 (45.2) | 962/1642 (58.6) | 1031/2508 (41.1) |
| Fully vaccinated with mRNA vaccine seriesd | 314 (100) | 0 | 1386 (54.8) |
| Among fully vaccinated, vaccine product received | |||
| BNT162b2 (Pfizer-BioNTech) | 226 (72.0) | 810/1386 (58.4) | |
| mRNA-1273 (Moderna) | 88 (28.0) | 576/1386 (41.6) | |
| Among fully vaccinated, median (IQR) days from second vaccine dose to onset of symptoms | 110.5 (58-141) | 79 (48-112) | |
Abbreviation: mRNA, messenger RNA.
Other includes self-reported race and ethnicity as other or non-Hispanic (n = 190), or patients for whom information on race and ethnicity was unavailable (n = 62).
Chronic medical conditions included the following (details in eTable 2 in the Supplement): cardiovascular disease, neurologic disease, pulmonary disease, gastrointestinal disease, endocrine disease, kidney disease, hematologic disease, malignancy, immunosuppression not captured in other categories, autoimmune condition, or other condition (sarcoidosis, amyloidosis, or unintentional weight loss ≥4.5 kg [10 lb] in the last 90 days).
Immunocompromising conditions included active solid organ cancer (active cancer defined as treatment for the cancer or newly diagnosed cancer in the past 6 months), active hematologic cancer (such as leukemia, lymphoma, or myeloma), HIV infection without AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ transplant, immunosuppressive medication, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, or inflammatory bowel disease, including Crohn disease or ulcerative colitis.
COVID-19 vaccination status included unvaccinated, defined as no receipt of any COVID-19 vaccine, and fully vaccinated, defined as receipt of at least 2 doses of an mRNA vaccine, with the second dose received at least 14 days before illness onset.